SLC5A2 and hydrops fetalis: Novel therapies including revolutionary drugs such as angiotensin receptor-neprilysin inhibitors (ARNI) and sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated their effectiveness in improving outcomes and promoting reverse remodeling in HF with reduced EF (HFrEF).